Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 32, 2010, Pages 14351-14356

  Hershfield, Michael S ^a   Roberts II, L Jackson ^b   Ganson, Nancy J ^a   Kelly, Susan J ^a   Santisteban, Ines ^a   Scarlett, Edna ^a   Jaggers, Denise ^a   Sundy, John S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

F2 isoprostanes; Hyperuricemia; Hypouricemia; Oxidative stress; Peroxiredoxin 2

Indexed keywords

ANTIOXIDANT; CATALASE; HYDROGEN PEROXIDE; PEGLOTICASE; UNCLASSIFIED DRUG; URATE OXIDASE; URIC ACID; ISOPROSTANE DERIVATIVE; MACROGOL DERIVATIVE; PROTEIN;

ADULT; ARTICLE; CELL DAMAGE; CELL FUNCTION; CLINICAL FEATURE; CLINICAL TRIAL; DRUG BLOOD LEVEL; ERYTHROCYTE COUNT; GOUT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID OXIDATION; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN CARBONYLATION; PROTEIN DEGRADATION; PROTEIN DEPLETION; TREATMENT RESPONSE; BLOOD; CELL CULTURE; CYTOLOGY; DRUG EFFECT; ERYTHROCYTE; METABOLISM; OXIDATION REDUCTION REACTION;

ANTIOXIDANTS; CELLS, CULTURED; ERYTHROCYTES; F2-ISOPROSTANES; GOUT; HUMANS; HYDROGEN PEROXIDE; OXIDATION-REDUCTION; OXIDATIVE STRESS; POLYETHYLENE GLYCOLS; PROTEINS; URATE OXIDASE; URIC ACID;

EID: 77956269930     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1001072107     Document Type: Article

References (58)

1. Kahn K, Tipton PA (1998) Spectroscopic characterization of intermediates in the urate oxidase reaction. Biochemistry 37:11651-11659. (Pubitemid 28388209)
2. Wu XW, Muzny DM, Lee CC, Caskey CT (1992) Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 34:78-84.
3. Roch-Ramel F, Peters G (1978) Urinary excretion of uric acid in nonhuman mammalian species. Handb Exp Pharmacol 51:211-255.
4. Ames BN, Cathcart R, Schwiers E, Hochstein P (1981) Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: A hypothesis. Proc Natl Acad Sci USA 78:6858-6862. (Pubitemid 12216861)
5. Frei B, England L, Ames BN (1989) Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci USA 86:6377-6381. (Pubitemid 19210655)
6. Ghiselli A, Serafini M, Natella F, Scaccini C (2000) Total antioxidant capacity as a tool to assess redox status: Critical view and experimental data. Free Radic Biol Med 29:1106-1114.
7. Ascherio A, et al.; Parkinson Study Group DATATOP Investigators (2009) Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 66:1460-1468.
8. Koch M, De Keyser J (2006) Uric acid in multiple sclerosis. Neurol Res 28:316-319.
9. Becker MA (2001) Hyperuricemia and gout. The Metabolic and Molecular Bases of Inherited Disease, eds Scriver CR, Beaudet AL, Sly WS, Valle D (McGraw-Hill, New York), 8th Ed, pp 2513-2535.
10. Saag KG, Mikuls TR (2005) Recent advances in the epidemiology of gout. Curr Rheumatol Rep 7:235-241.
11. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R (2004) Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 31:1582-1587. (Pubitemid 39006641)
12. Choi HK, Curhan G (2007) Independent impact of gout on mortality and risk for coronary heart disease. Circulation 116:894-900. (Pubitemid 47300913)
13. Choi HK, Ford ES, Li C, Curhan G (2007) Prevalence of the metabolic syndrome in patients with gout: The Third National Health and Nutrition Examination Survey. Arthritis Rheum 57:109-115. (Pubitemid 46256732)
14. Cirillo P, et al. (2006) Uric acid, the metabolic syndrome, and renal disease. J Am Soc Nephrol 17(12, Suppl 3)S165-S168.
15. Feig DI, Soletsky B, Johnson RJ (2008) Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: A randomized trial. JAMA 300:924-932.
16. Ioachimescu AG, Brennan DM, Hoar BM, Hazen SL, Hoogwerf BJ (2008) Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: A preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum 58:623-630.
17. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH, MRFIT Research Group (2008) Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 168:1104-1110. (Pubitemid 351749228)
18. Strasak A, et al.; VHM&PP Study Group (2008) Serum uric acid and risk of cardiovascular mortality: A prospective long-term study of 83,683 Austrian men. Clin Chem 54:273-284.
19. Sundy JS, et al.; Pegloticase Phase 2 Study Investigators (2008) Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study. Arthritis Rheum 58:2882-2891.
20. Sundy JS, et al. (2007) Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 56:1021-1028.
21. Hershfield MS (2009) Reassessing serum urate targets in the management of refractory gout: Can you go too low? Curr Opin Rheumatol 21:138-142.
22. Perez-Ruiz F, Lioté F (2007) Lowering serum uric acid levels: What is the optimal target for improving clinical outcomes in gout? Arthritis Rheum 57:1324-1328.
23. Basu S (2008) F2-isoprostanes in human health and diseases: From molecular mechanisms to clinical implications. Antioxid Redox Signal 10:1405-1434.
24. Levine RL (2002) Carbonyl modified proteins in cellular regulation, aging, and disease. Free Radic Biol Med 32:790-796.
25. Terkeltaub R (2009) Gout. Novel therapies for treatment of gout and hyperuricemia. Arthritis Res Ther 11:236.
26. Agar NS, Sadrzadeh SMH, Hallaway PE, Eaton JW (1986) Erythrocyte catalase. A somatic oxidant defense? J Clin Invest 77:319-321.
27. Winterbourn CC, Stern A (1987) Human red cells scavenge extracellular hydrogen peroxide and inhibit formation of hypochlorous acid and hydroxyl radical. J Clin Invest 80:1486-1491.
28. Low FM, Hampton MB, Peskin AV, Winterbourn CC (2007) Peroxiredoxin 2 functions as a noncatalytic scavenger of low-level hydrogen peroxide in the erythrocyte. Blood 109:2611-2617.
29. Low FM, Hampton MB, Winterbourn CC (2008) Peroxiredoxin 2 and peroxide metabolism in the erythrocyte. Antioxid Redox Signal 10:1621-1630.
30. Manta B, et al. (2009) The peroxidase and peroxynitrite reductase activity of human erythrocyte peroxiredoxin 2. Arch Biochem Biophys 484:146-154.
31. Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS (2006) Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 8:R12.
32. Morrow JD, Awad JA, Boss HJ, Blair IA, Roberts LJ, 2nd (1992) Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc Natl Acad Sci USA 89:10721-10725.
33. Kadiiska MB, et al. (2005) Biomarkers of oxidative stress study II: Are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med 38:698-710.
34. Morrow JD, Roberts LJ, 2nd (1999) Mass spectrometric quantification of F2-isoprostanes in biological fluids and tissues as measure of oxidant stress. Methods Enzymol 300:3-12.
35. Block G, et al. (2008) The effect of vitamins C and E on biomarkers of oxidative stress depends on baseline level. Free Radic Biol Med 45:377-384.
36. Keaney JF, Jr, et al.; Framingham Study (2003) Obesity and systemic oxidative stress: Clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 23:434-439.
37. Morrow JD, et al. (1995) Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 332:1198-1203.
38. Paton LN, Mocatta TJ, Richards AM, Winterbourn CC (2010) Increased thrombin-induced polymerization of fibrinogen associated with high protein carbonyl levels in plasma from patients post myocardial infarction. Free Radic Biol Med 48:223-229.
39. Sinha S, Singh SN, Ray US (2009) Total antioxidant status at high altitude in lowlanders and native highlanders: Role of uric acid. High Alt Med Biol 10:269-274.
40. Tsukimori K, Yoshitomi T, Morokuma S, Fukushima K, Wake N (2008) Serum uric acid levels correlate with plasma hydrogen peroxide and protein carbonyl levels in preeclampsia. Am J Hypertens 21:1343-1346.
41. Andreadou E, et al. (2009) Serum uric acid levels in patients with Parkinson's disease: Their relationship to treatment and disease duration. Clin Neurol Neurosurg 111 (9):724-728.
42. Chen H, Mosley TH, Alonso A, Huang X (2009) Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 169:1064-1069.
43. Koprowski H, Spitsin SV, Hooper DC (2001) Prospects for the treatment of multiple sclerosis by raising serum levels of uric acid, a scavenger of peroxynitrite. Ann Neurol 49:139.
44. Langemann H, Feuerstein T, Mendelowitsch A, Gratzl O (2001) Microdialytical monitoring of uric and ascorbic acids in the brains of patients after severe brain injury and during neurovascular surgery. J Neurol Neurosurg Psychiatry 71:169-174.
45. Tohgi H, Abe T, Takahashi S, Kikuchi T (1993) The urate and xanthine concentrations in the cerebrospinal fluid in patients with vascular dementia of the Binswanger type, Alzheimer type dementia, and Parkinson's disease. J Neural Transm Park Dis Dement Sect 6:119-126.
46. Santos CX, Anjos EI, Augusto O (1999) Uric acid oxidation by peroxynitrite: Multiple reactions, free radical formation, and amplification of lipid oxidation. Arch Biochem Biophys 372:285-294.
47. Squadrito GL, et al. (2000) Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys 376:333-337.
48. Whiteman M, Ketsawatsakul U, Halliwell B (2002) A reassessment of the peroxynitrite scavenging activity of uric acid. Ann N Y Acad Sci 962:242-259.
49. Gersch C, et al. (2009) Reactions of peroxynitrite with uric acid: Formation of reactive intermediates, alkylated products and triuret, and in vivo production of triuret under conditions of oxidative stress. Nucleosides Nucleotides Nucleic Acids 28:118-149.
50. Patterson RA, Horsley ET, Leake DS (2003) Prooxidant and antioxidant properties of human serum ultrafiltrates toward LDL: Important role of uric acid. J Lipid Res 44:512-521.
51. Gonsette RE, et al.; ASIIMS study group (2010) Boosting endogenous neuroprotection in multiple sclerosis: The Association of Inosine and Interferon beta in relapsing-remitting Multiple Sclerosis (ASIIMS) trial. Mult Scler 16:455-462.
52. Ichida K, et al. (2004) Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 15:164-173.
53. Raivio KO, Saksela M, Lapatto R (2001) Xanthine oxidoreductase - role in human pathophysiology and in hereditary xanthinuria. The Metabolic and Molecular Bases of Inherited Disease, eds Scriver CR, Beaudet AL, Sly WS, Valle D (McGraw-Hill, New York), 8th Ed, pp 2639-2652.
54. Kelly SJ, et al. (2001) Diabetes insipidus in uricase-deficient mice: A model for evaluating therapy with poly(ethylene glycol)-modified uricase. J Am Soc Nephrol 12:1001-1009.
55. Wu X, et al. (1994) Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proc Natl Acad Sci USA 91:742-746.
56. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237-241.
57. So A (2008) Developments in the scientific and clinical understanding of gout. Arthritis Res Ther 10:221.
58. Baraf HS, Matsumoto AK, Maroli AN, Waltrip RW, 2nd (2008) Resolution of gouty tophi after twelve weeks of pegloticase treatment. Arthritis Rheum 58:3632-3634.